Knee osteoarthritis (OA) involves progressive degeneration of articular cartilage, underlying bone, and synovial tissue, culminating in pain, stiffness, and reduced mobility.
Knee osteoarthritis (OA) involves progressive degeneration of articular cartilage, underlying bone, and synovial tissue, culminating in pain, stiffness, and reduced mobility. Stem cell approaches exploit the regenerative capacity of placental mesenchymal stem cells (MSCs), which differentiate into chondrocytes (cartilage cells) and secrete anti-inflammatory cytokines. Chondrocytes derived from donor cartilage offer direct cartilage replacement. Exosomes from stem cells deliver growth factors into the joint space, potentially halting inflammatory cascades and stimulating endogenous repair. The therapeutic hypothesis is twofold: structural regeneration of damaged cartilage and immunological resolution of synovial inflammation driving pain. One hundred sixty-six registered trials globally reflect intense commercial and academic interest. Sixteen trials are actively recruiting, indicating rapid expansion of treatment capacity.
| 指示性成本 · 保加利亚 (EU) | €3,000–€8,000 |
|---|---|
| 全球市场成本范围 | €2,760–€9,200 (orthorepair.com) |
| 研究的主要细胞类型 | MSCs from Amniotic Membrane, Chondrocytes, Exosomes |
| 批准状态 | 研究性 |
| 注册的临床试验 (ClinicalTrials.gov) | 166 · 16 recruiting now |
For the clinic's own description, see how Stem Plus describes its Knee Osteoarthritis programme ↗.
Comprehensive evidence synthesis across 166 trials remains ongoing; no systematic review with meta-analysis has been published to date. Published phase II/III trials report pain reduction (measured by WOMAC or numerical pain scales) of 30–50% in 50–70% of participants by 6 months. Imaging studies show variable results: some demonstrate cartilage thickening on MRI; others show no structural change despite pain improvement. Durability studies suggest benefit persists 12–24 months in responders. Comparative trials versus hyaluronic acid or corticosteroid injection show modest superiority of cell-based therapy. Long-term follow-up (≥5 years) in large cohorts is lacking; most evidence derives from small, single-centre studies.
Depending on assessment, a Knee Osteoarthritis protocol may draw on:
Knee OA cell therapy ranges from €3,500–6,500 per knee in European centres. Placental MSC intra-articular injection (€4,000–5,500) is most common. Autologous chondrocyte implantation commands premium pricing (€6,000–8,000) owing to required surgical harvest and extended culture. Exosome-based intra-articular therapies cost €3,500–5,000. Bilateral knees require separate procedures, doubling cost. Repeat injections (often recommended at 6–12 month intervals) significantly increase lifetime expenditure. Insurance selectively reimburses in some European countries (e.g., Spain, Germany) under medical necessity frameworks; US coverage is rare.
Indicative EU treatment cost is €3,000–€8,000 versus roughly €15,000–35,000 in the US or Germany. Build your real all-in total with the cost calculator, see the Knee Osteoarthritis cost-by-country breakdown, or compare the best countries for Knee Osteoarthritis →
Before booking, check safety & regulation, the recovery climate, 您是否可能是候选人, and which cell type fits Knee Osteoarthritis.
完整膝关节骨关节炎常见问题 → · 膝关节骨关节炎成本分解 →
We link primary regulators, registries and peer-reviewed research so you can verify everything yourself — plus the treating clinic's own materials.
Useful tools & guides: 我是候选人吗？ · 哪种细胞类型？ · Types of clinics & best countries · 成本计算器
由 StemCellAtlas 的编辑团队进行医学审查，与Dr Tymur Lukyanenko (Orthopaedic Traumatologist · 20+ yrs clinical, 15+ yrs cell therapy) 合作诊所 Stem Plus（索菲亚）的，根据 ISSCR、FDA 和 EMA 指南。 Educational information, not medical advice; figures indicative.
位于欧盟核心的 GMP 认证再生医学诊所——费用 3,000–8,000 欧元起，仅为美国或德国价格的一小部分。为来自 50 多个国家的国际患者提供个性化方案。
免费医疗评估